Roquefort Therapeutics plc (ROQ.L) Research

Roquefort Therapeutics plc functions as a biotechnology firm, focusing its efforts on the discovery and development of innovative pharmaceutical treatments. The company's primary research objective is to develop therapies that target Midkine, a circulating growth factor protein and pro-inflammatory mediator, for applications in cancer treatment. Established in 2020, Roquefort Therapeutics plc has its main operations based in London, United Kingdom.

Market snapshot

Symbol
ROQ.L
Price
$0.95
Day change
-5.00%
Market cap
$155.5K
P/E ratio
-0.16x
52-week range
0.9-3
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Cizzle Biotechnology Holdings Plc (CIZ.L)
  • CRISM Therapeutics Corporation (CRTX.L)
  • Feedback plc (FDBK.L)
  • MyHealthChecked PLC (MHC.L)
  • Polarean Imaging plc (POLX.L)
  • Proteome Sciences plc (PRM.L)
  • Physiomics Plc (PYC.L)
  • Theracryf Plc (TCF.L)

Open Roquefort Therapeutics plc (ROQ.L) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.